Meltem Akgül Erdal, Halime Nayır Büyükşahin, Velat Şen, Ayşe Ayzıt Kılınç, Haluk Çokuğraş, Güzide Doğan, Aslı İmran Yılmaz, Gökçen Ünal, Mahir Serbes, Derya Ufuk Altıntaş, Elif Arık, Özlem Keskin, Mehmet Mustafa Özaslan, Oğuz Karcıoğlu, Mehmet Köse, Abdurrahman Erdem Başaran, Eylül Pınar Çakır, Yakup Canıtez, Ali Özdemir, Koray Harmancı, Salih Uytun, Sanem Eryılmaz Polat, Melih Hangül, Hasan Yüksel, Gizem Özcan, Pervin Korkmaz, Mehmet Kılıç, Zeynep Gökçe Gayretli Aydın, Gönül Çaltepe, Demet Can, Sibel Doğru, Gökçen Kartal Öztürk, Ayşe Süleyman, Erdem Topal, Beste Özsezen, Mina Hızal, Ezgi Demirdöğen, Hamza Ogun, Şermin Börekçi, Hakan Yazan, Hadice Selimoğlu Şen, Ayşegül Doğan Demir, Erkan Çakır, Tuğba Şişmanlar Eyüboğlu, Nagehan Emiralioğlu, Sevgi Pekcan, Uğur Özçelik, Deniz Doğru
{"title":"囊性纤维化跨膜传导调节剂（CFTR）调节剂治疗的资格：t<s:1> rkiye囊性纤维化登记队列。","authors":"Meltem Akgül Erdal, Halime Nayır Büyükşahin, Velat Şen, Ayşe Ayzıt Kılınç, Haluk Çokuğraş, Güzide Doğan, Aslı İmran Yılmaz, Gökçen Ünal, Mahir Serbes, Derya Ufuk Altıntaş, Elif Arık, Özlem Keskin, Mehmet Mustafa Özaslan, Oğuz Karcıoğlu, Mehmet Köse, Abdurrahman Erdem Başaran, Eylül Pınar Çakır, Yakup Canıtez, Ali Özdemir, Koray Harmancı, Salih Uytun, Sanem Eryılmaz Polat, Melih Hangül, Hasan Yüksel, Gizem Özcan, Pervin Korkmaz, Mehmet Kılıç, Zeynep Gökçe Gayretli Aydın, Gönül Çaltepe, Demet Can, Sibel Doğru, Gökçen Kartal Öztürk, Ayşe Süleyman, Erdem Topal, Beste Özsezen, Mina Hızal, Ezgi Demirdöğen, Hamza Ogun, Şermin Börekçi, Hakan Yazan, Hadice Selimoğlu Şen, Ayşegül Doğan Demir, Erkan Çakır, Tuğba Şişmanlar Eyüboğlu, Nagehan Emiralioğlu, Sevgi Pekcan, Uğur Özçelik, Deniz Doğru","doi":"10.24953/turkjpediatr.2025.4680","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variants are essential for determining eligibility for CFTR modulator drugs (CFTRms). In contrast to Europe and the USA, the treatment eligibility profile of cystic fibrosis (CF) patients in Türkiye is not known. In this study we aimed to determine the eligibility of CF patients in Türkiye for the CFTRms.</p><p><strong>Methods: </strong>The Cystic Fibrosis Registry of Türkiye (CFrT) data was used to determine the age of patients in the year 2021 and the genetic variants they were carrying. Age- and CFTR-variant appropriate modulator therapies were determined using the Vertex® algorithm.</p><p><strong>Results: </strong>Among a total of 1930 registered patients, CTFR gene analysis was performed on a total of 1841 (95.4%) patients. Mutations were detected in one allele in 10.7% (198 patients), and in both alleles in 79% (1455 patients) of patients. A total of 855 patients (51.7% for whom at least 1 mutation was detected) were eligible for the drugs. The most appropriate drug among genotyped patients was found to be elexacaftor/tezacaftor/ivacaftor for 486 patients (26.4%), followed by ivacaftor for 327 patients (17.7%) and lumacaftor/ivacaftor for 42 patients (2%).</p><p><strong>Conclusions: </strong>Only half of patients registered in CFrT were eligible for CFTRms, which is a significant difference from the CFTR variant profile seen in USA and Europe. However, access to treatment is hampered for some patients whose genes are not analysed. Further studies in CF populations, where rare mutations are relatively more common, will contribute to the field of CFTR modulator treatments for such rare mutations.</p>","PeriodicalId":101314,"journal":{"name":"The Turkish journal of pediatrics","volume":"67 1","pages":"22-30"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Eligibility of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapies: cohort of cystic fibrosis registry of Türkiye.\",\"authors\":\"Meltem Akgül Erdal, Halime Nayır Büyükşahin, Velat Şen, Ayşe Ayzıt Kılınç, Haluk Çokuğraş, Güzide Doğan, Aslı İmran Yılmaz, Gökçen Ünal, Mahir Serbes, Derya Ufuk Altıntaş, Elif Arık, Özlem Keskin, Mehmet Mustafa Özaslan, Oğuz Karcıoğlu, Mehmet Köse, Abdurrahman Erdem Başaran, Eylül Pınar Çakır, Yakup Canıtez, Ali Özdemir, Koray Harmancı, Salih Uytun, Sanem Eryılmaz Polat, Melih Hangül, Hasan Yüksel, Gizem Özcan, Pervin Korkmaz, Mehmet Kılıç, Zeynep Gökçe Gayretli Aydın, Gönül Çaltepe, Demet Can, Sibel Doğru, Gökçen Kartal Öztürk, Ayşe Süleyman, Erdem Topal, Beste Özsezen, Mina Hızal, Ezgi Demirdöğen, Hamza Ogun, Şermin Börekçi, Hakan Yazan, Hadice Selimoğlu Şen, Ayşegül Doğan Demir, Erkan Çakır, Tuğba Şişmanlar Eyüboğlu, Nagehan Emiralioğlu, Sevgi Pekcan, Uğur Özçelik, Deniz Doğru\",\"doi\":\"10.24953/turkjpediatr.2025.4680\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variants are essential for determining eligibility for CFTR modulator drugs (CFTRms). In contrast to Europe and the USA, the treatment eligibility profile of cystic fibrosis (CF) patients in Türkiye is not known. In this study we aimed to determine the eligibility of CF patients in Türkiye for the CFTRms.</p><p><strong>Methods: </strong>The Cystic Fibrosis Registry of Türkiye (CFrT) data was used to determine the age of patients in the year 2021 and the genetic variants they were carrying. Age- and CFTR-variant appropriate modulator therapies were determined using the Vertex® algorithm.</p><p><strong>Results: </strong>Among a total of 1930 registered patients, CTFR gene analysis was performed on a total of 1841 (95.4%) patients. Mutations were detected in one allele in 10.7% (198 patients), and in both alleles in 79% (1455 patients) of patients. A total of 855 patients (51.7% for whom at least 1 mutation was detected) were eligible for the drugs. The most appropriate drug among genotyped patients was found to be elexacaftor/tezacaftor/ivacaftor for 486 patients (26.4%), followed by ivacaftor for 327 patients (17.7%) and lumacaftor/ivacaftor for 42 patients (2%).</p><p><strong>Conclusions: </strong>Only half of patients registered in CFrT were eligible for CFTRms, which is a significant difference from the CFTR variant profile seen in USA and Europe. However, access to treatment is hampered for some patients whose genes are not analysed. Further studies in CF populations, where rare mutations are relatively more common, will contribute to the field of CFTR modulator treatments for such rare mutations.</p>\",\"PeriodicalId\":101314,\"journal\":{\"name\":\"The Turkish journal of pediatrics\",\"volume\":\"67 1\",\"pages\":\"22-30\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Turkish journal of pediatrics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24953/turkjpediatr.2025.4680\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Turkish journal of pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24953/turkjpediatr.2025.4680","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Eligibility of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapies: cohort of cystic fibrosis registry of Türkiye.
Background: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variants are essential for determining eligibility for CFTR modulator drugs (CFTRms). In contrast to Europe and the USA, the treatment eligibility profile of cystic fibrosis (CF) patients in Türkiye is not known. In this study we aimed to determine the eligibility of CF patients in Türkiye for the CFTRms.
Methods: The Cystic Fibrosis Registry of Türkiye (CFrT) data was used to determine the age of patients in the year 2021 and the genetic variants they were carrying. Age- and CFTR-variant appropriate modulator therapies were determined using the Vertex® algorithm.
Results: Among a total of 1930 registered patients, CTFR gene analysis was performed on a total of 1841 (95.4%) patients. Mutations were detected in one allele in 10.7% (198 patients), and in both alleles in 79% (1455 patients) of patients. A total of 855 patients (51.7% for whom at least 1 mutation was detected) were eligible for the drugs. The most appropriate drug among genotyped patients was found to be elexacaftor/tezacaftor/ivacaftor for 486 patients (26.4%), followed by ivacaftor for 327 patients (17.7%) and lumacaftor/ivacaftor for 42 patients (2%).
Conclusions: Only half of patients registered in CFrT were eligible for CFTRms, which is a significant difference from the CFTR variant profile seen in USA and Europe. However, access to treatment is hampered for some patients whose genes are not analysed. Further studies in CF populations, where rare mutations are relatively more common, will contribute to the field of CFTR modulator treatments for such rare mutations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
